Thalidomide-O-PEG4-C2-acid

Background Introduction

Thalidomide-O-PEG4-C2-acid is a specialized E3 ligase ligand-linker conjugate designed for advanced drug discovery applications, particularly in the development of PROTACs (Proteolysis Targeting Chimeras). Incorporating the thalidomide-based cereblon (CRBN) ligand, a PEG4 spacer, and a carboxylic acid functional group, this molecule serves as a versatile intermediate for constructing targeted protein degraders.

Mechanism

The mechanism of Thalidomide-O-PEG4-C2-acid centers on its role as an E3 ligase recruiter within bifunctional molecules like PROTACs. The thalidomide moiety selectively binds to cereblon, an E3 ubiquitin ligase substrate receptor, facilitating the recruitment of the ubiquitin-proteasome system. The PEG4 linker provides optimal spatial orientation and flexibility, while the C2-acid allows for efficient conjugation with a wide variety of target protein ligands. When incorporated into a PROTAC, Thalidomide-O-PEG4-C2-acid enables proximity-induced ubiquitination and subsequent proteasomal degradation of the target protein.

Applications

Thalidomide-O-PEG4-C2-acid is widely used in the design and synthesis of cereblon-based PROTACs for targeted protein degradation. Its applications include the development of chemical tools for elucidating protein function, validation of new therapeutic targets, and pioneering new treatment strategies in oncology, neurodegeneration, and other disease areas. This conjugate is valued for its compatibility in medicinal chemistry workflows, allowing for efficient assembly of multifunctional degraders that exploit the ubiquitin-proteasome pathway.

• Polyethylene glycol (PEG4) linker improves solubility and pharmacokinetic properties in PROTAC design.
• Carboxylic acid functional group allows flexible conjugation with diverse warheads and bioactive molecules.

Thalidomide-O-PEG4-C2-acid is an innovative E3 Ligase Ligand-Linker Conjugate utilized in PROTACs for targeted protein degradation, offering unique structural advantages. It effectively bridges the E3 ligase and target protein, enhancing selectivity and efficacy. The following provides a detailed description of this molecule, focusing on its linker, ligand, and the selection of target protein ligands.

Linker: This molecule features a PEG4 linker, known for its optimal length and flexibility, which facilitates efficient molecular interactions. The PEG4 structure provides hydrophilicity and enhances solubility, while its flexibility allows for effective spatial orientation. The C2-acid moiety at the end of the linker adds a cleavable site, enabling controlled release.

Ligand: The ligand in this molecule is based on thalidomide, a well-characterized E3 ligase binder. Its structural characteristics include a phthalimide moiety, which is essential for binding to the cereblon (CRBN) E3 ligase, promoting ubiquitination and subsequent proteasomal degradation of the target protein.

Reactive Site: The terminal carboxylic acid group of the C2-acid serves as the reactive site, facilitating coupling with the target protein ligand. Recommended reaction types include amide bond formation, which ensures stable linkage and efficient conjugation under mild conditions, preserving the integrity of both the ligand and the target protein.

Recommended Target Protein Ligand: Suitable warheads for this molecule include those with primary amines, which can react with the C2-acid to form stable amide bonds. This compatibility allows for the development of highly specific PROTACs, enhancing the degradation of target proteins. Applications include the selective degradation of oncogenic proteins, offering a promising approach for cancer research and therapeutic development.